189 related articles for article (PubMed ID: 35311228)
41. Aryl hydrocarbon receptor interacting protein mutations seem not to associate with familial non-medullary thyroid cancer.
Raitila A; Georgitsi M; Bonora E; Vargiolu M; Tuppurainen K; Mäkinen MJ; Vierimaa O; Salmela PI; Launonen V; Vahteristo P; Aaltonen LA; Romeo G; Karhu A
J Endocrinol Invest; 2009 May; 32(5):426-9. PubMed ID: 19794292
[TBL] [Abstract][Full Text] [Related]
42. Is familial non-medullary thyroid carcinoma more aggressive than sporadic thyroid cancer? A multicenter series.
Alsanea O; Wada N; Ain K; Wong M; Taylor K; Ituarte PH; Treseler PA; Weier HU; Freimer N; Siperstein AE; Duh QY; Takami H; Clark OH
Surgery; 2000 Dec; 128(6):1043-50;discussion 1050-1. PubMed ID: 11114641
[TBL] [Abstract][Full Text] [Related]
43. FAMILIAL NON-MEDULLARY THYROID CARCINOMA.
Guda BB; Komisarenko II; Ostafiichuk MV; Tronko MD
Exp Oncol; 2023 Jun; 45(1):70-78. PubMed ID: 37417280
[TBL] [Abstract][Full Text] [Related]
44. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.
Cirello V; Colombo C; Karapanou O; Pogliaghi G; Persani L; Fugazzola L
Front Endocrinol (Lausanne); 2020; 11():589340. PubMed ID: 33488516
[TBL] [Abstract][Full Text] [Related]
45. Diagnosis and Management of Hereditary Thyroid Cancer.
Bano G; Hodgson S
Recent Results Cancer Res; 2016; 205():29-44. PubMed ID: 27075347
[TBL] [Abstract][Full Text] [Related]
46. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy.
Lang BH; Wong IO; Wong KP; Cowling BJ; Wan KY
Surgery; 2012 Jun; 151(6):844-50. PubMed ID: 22341041
[TBL] [Abstract][Full Text] [Related]
47. [Next generation sequencing technology for susceptible gene screening in familial non-medullary thyroid carcinoma].
Dong L; Yu Y; Yu JP; Hao WJ; Zheng XQ; Cheng YN; Han L; Zhao JZ; Gao M
Zhonghua Zhong Liu Za Zhi; 2017 Jan; 39(1):24-28. PubMed ID: 28104029
[No Abstract] [Full Text] [Related]
48. Familial non-medullary thyroid cancer: a matched-case control study.
Maxwell EL; Hall FT; Freeman JL
Laryngoscope; 2004 Dec; 114(12):2182-6. PubMed ID: 15564841
[TBL] [Abstract][Full Text] [Related]
49. Genetics of Familial Non-Medullary Thyroid Carcinoma (FNMTC).
Diquigiovanni C; Bonora E
Cancers (Basel); 2021 Apr; 13(9):. PubMed ID: 33946592
[TBL] [Abstract][Full Text] [Related]
50. Identification of Novel Candidate Genes for Familial Thyroid Cancer by Whole Exome Sequencing.
Tous C; Muñoz-Redondo C; Bravo-Gil N; Gavilan A; Fernández RM; Antiñolo J; Navarro-González E; Antiñolo G; Borrego S
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175550
[TBL] [Abstract][Full Text] [Related]
51. Familial Non-Medullary Thyroid Carcinoma in Pediatric Age: Our Surgical Experience.
Spinelli C; Piccolotti I; Bertocchini A; Morganti R; Materazzi G; Tonacchera M; Strambi S
World J Surg; 2021 Aug; 45(8):2473-2479. PubMed ID: 33891138
[TBL] [Abstract][Full Text] [Related]
52. [Clinical and biological features of familial nonmedullary thyroid carcinoma].
Gao J; Yu Y; Li X; Zhao J; Zhao C; Zhao J; Liu Y; Li Y; Gao M
Zhonghua Zhong Liu Za Zhi; 2014 Mar; 36(3):202-6. PubMed ID: 24785281
[TBL] [Abstract][Full Text] [Related]
53. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
[TBL] [Abstract][Full Text] [Related]
54. Familial occurrence of nonmedullary thyroid cancer: a population-based study of 5673 first-degree relatives of thyroid cancer patients from Norway.
Frich L; Glattre E; Akslen LA
Cancer Epidemiol Biomarkers Prev; 2001 Feb; 10(2):113-7. PubMed ID: 11219767
[TBL] [Abstract][Full Text] [Related]
55. Non-medullary Thyroid Cancer Susceptibility Genes: Evidence and Disease Spectrum.
Zhou J; Singh P; Yin K; Wang J; Bao Y; Wu M; Pathak K; McKinley SK; Braun D; Lubitz CC; Hughes KS
Ann Surg Oncol; 2021 Oct; 28(11):6590-6600. PubMed ID: 33660127
[TBL] [Abstract][Full Text] [Related]
56. Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene.
Matakidou A; Hamel N; Popat S; Henderson K; Kantemiroff T; Harmer C; Clarke SE; Houlston RS; Foulkes WD
Carcinogenesis; 2004 Mar; 25(3):369-73. PubMed ID: 14633662
[TBL] [Abstract][Full Text] [Related]
57. Results of Screening in Familial Non-Medullary Thyroid Cancer.
Klubo-Gwiezdzinska J; Yang L; Merkel R; Patel D; Nilubol N; Merino MJ; Skarulis M; Sadowski SM; Kebebew E
Thyroid; 2017 Aug; 27(8):1017-1024. PubMed ID: 28657510
[TBL] [Abstract][Full Text] [Related]
58. Familial non-medullary thyroid carcinoma: pathology review in 27 affected cases from 13 French families.
Leprat F; Bonichon F; Guyot M; Trouette H; Trojani M; Vergnot V; Longy M; Belleannée G; de Mascarel A; Roger P
Clin Endocrinol (Oxf); 1999 May; 50(5):589-94. PubMed ID: 10468924
[TBL] [Abstract][Full Text] [Related]
59. Coincidence of primary hyperparathyroidism and nonmedullary thyroid carcinoma.
Lehwald N; Cupisti K; Krausch M; Ahrazoglu M; Raffel A; Knoefel WT
Horm Metab Res; 2013 Sep; 45(9):660-3. PubMed ID: 23757116
[TBL] [Abstract][Full Text] [Related]
60. Familial Non-Medullary Thyroid Cancer Represents an Independent Risk Factor for Increased Cancer Aggressiveness: A Retrospective Analysis of 74 Families.
Tavarelli M; Russo M; Terranova R; Scollo C; Spadaro A; Sapuppo G; Malandrino P; Masucci R; Squatrito S; Pellegriti G
Front Endocrinol (Lausanne); 2015; 6():117. PubMed ID: 26284028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
